Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 9:59 PM
Ignite Modification Date:
2025-12-25 @ 7:36 PM
NCT ID:
NCT03111732
Group ID:
EG000
Title:
1/Arm 1 - Pembrolizumab Plus Oxaliplatin Plus Capecitabine
Description:
Pembrolizumab plus Oxaliplatin plus Capecitabine
Pembrolizumab (MK-3475): 200 mg will be administered as an intravenous (IV) infusion on Day 1 of each 21 day cycle
Oxaliplatin: 130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
Capecitabine: 750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
Deaths Number Affected:
9
Deaths Number At Risk:
None
Serious Number Affected:
4
Serious Number At Risk:
11
Other Number Affected:
11
Other Number At Risk:
11
Study:
NCT03111732
Results Section:
NCT03111732
Adverse Events Module:
NCT03111732